Lopinavir/ritonavir: towards simplifying therapy in HIV infection

    loading  Checking for direct PDF access through Ovid


Combination antiretroviral therapy has greatly decreased the morbidity and mortality associated with HIV infection, although many agents currently available are limited by difficult dosing requirements, side-effect profiles and the development of resistance. Lopinavir/ritonavir is a coformulation of two protease inhibitors that exploit a favorable drug–drug interaction, yielding sustained increases in plasma levels of lopinavir. This agent has shown excellent therapeutic efficacy in both antiretroviral-naïve and –experienced patients, with a tolerable side-effect profile and without evidence of the development of primary resistance mutations in registrational trials. Once-daily dosing has been approved recently for use in antiretroviral-naïve patients, and US FDA approval was granted recently for a new tablet formulation that decreases the number of pills required for standard dosing.

Related Topics

    loading  Loading Related Articles